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Summary 
 
 
  
 
5F-PB-22 (quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) is a synthetic cannabinoid 
receptor agonist (SCRA) that had no history in the scientific literature until its detection emerged 
in 2013. This substance has been encountered as a synthetic constituent found in herbal smoking 
mixtures that are sold under a variety of brand names. It is common for retailers to purchase bulk 
quantities of the synthetic substance and add the synthetic material to plant matter that is then 
distributed onto the market. However, 5F-PB-22 is also available in powdered form as a “research 
chemical”. Various UN Member States reported the identification of 5F-PB-22 first in 2013 and 
data obtained from law enforcement suggest that 5F-PB-22 emerged and peaked in 2013 and 2014 
in the United States of America, which then dropped in the following years.  
 
A small number of in vitro and in vivo studies are currently available but the data indicate that 5F-
PB-22 binds to and activates human CB1 and CB2 receptors at low nanomolar concentrations, and 
that it induces a number of biological responses also triggered by the naturally occurring 
phytocannabinoid Δ9-THC. In some in vitro assays, 5F-PB-22 acted as a full at both cannabinoid 
receptors. 5F-PB-22 also fully substituted for Δ9-THC in the drug discrimination paradigm and 
was ~22 times more potent than the training drug, which suggests that 5F-PB-22 may have abuse 
liability similar to Δ9-THC and/or other internationally controlled synthetic cannabinoid receptor 
agonists.   
 
Reports indicate an increasing trend for SCRAs being implicated in mini epidemics that have been 
associated with severe adverse drug effects including deaths. Reported adverse drug reactions 
associated with a range of SCRAs frequently include gastrointestinal (e.g. nausea/hyperemesis), 
neurological (e.g. hallucination, agitation, anxiety, paranoia, confusion, delusions, catatonia, 
lethargy, psychosis (including susceptible individuals)), cardiovascular (e.g. tachycardia, 
hypertension) and renal (e.g. acute kidney failure) features.  
 
The total number of cases reported in the scientific literature that make a causal link with 5F-PB-
22 is very small. Intoxications and deaths associated with 5F-PB-22 have been reported but very 
few details are available. ‘Driving Under the Influence’ cases linked to 5F-PB-22 intoxication 
revealed significant impairment.   
 
Although not specific to 5F-PB-22, there are indications that socially vulnerable and stigmatized 
drug users for example found in homeless and prison populations, are increasingly associated 
with problematic use of SCRA products. Heavy use of SCRAs has been associated with 
problematic withdrawal symptoms and further research is needed to investigate the underlying 
mechanisms. Epidemiological data, such as prevalence of use, abuse and dependence information 
specifically related to 5F-PB-22 could not be identified. 
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1. Substance identification  
A. International Nonproprietary Name (INN) 
Not available. 
B. Chemical Abstract Service (CAS) Registry Number 
1400742-41-7 (free base) 
C. Other Chemical Names 
1-(5-Fluoropentyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester; 
8-Quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid 
D. Trade Names 
Not available. 
E. Street Names 
5F-PB-22; 5-fluoro-PB-22; 5F-QUPIC; QCBL-2201;1 PB-22F;1 MN-25F;1 QUPIC 
N-(5-fluoropentyl) analog. 
F. Physical Appearance 
5F-PB-22 has been described as a crystalline solid,2 white powder3 and off-
white/tan crystalline solid.4 
G. WHO Review History 
5F-PB-22 has not been previously pre-reviewed or critically reviewed. A direct 
critical review is proposed based on information brought to WHO’s attention that 
5F-PB-22 is clandestinely manufactured, of especially serious risk to public health 
and society, and of no recognized therapeutic use by any party. Preliminary data 
collected from literature and different countries indicated that this substance may 
cause substantial harm and that it has no medical use. 
 
2. Chemistry 
A. Chemical Name 
IUPAC Name: Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate 
CA Index Name: 1H-Indole-3-carboxylic acid, 1-(5-fluoropentyl)-, 8-
quinolinyl ester 
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B. Chemical Structure 
Free base: 
 
 
Molecular Formula: C23H21FN2O2 
Molecular Weight: 376.43 g/mol 
  
C. Stereoisomers 
Not applicable. 
D. Methods and Ease of Illicit Manufacturing 
The preparation of 5F-PB-22 is straightforward and follows standard procedures 
starting from indole (1). Indole N-alkylation followed by indole acylation and 
saponification provides the carboxylic acid intermediate (2). Conversion to the acid 
chloride intermediate (3) is then followed by reaction with 8-hydroxyquinoline to 
yield the ester product 5F-PB-22 (4).4  
 
 
(a) NaH (2.0 equiv), Br(CH2)4 F, DMF, 0 °C to rt, then (CF3CO)2O, 0 °C to rt, 1 h; next step: KOH, 
MeOH, PhMe, reflux, 2 h; (b) (f) (COCl)2, DMF (cat.), CH2Cl2, rt, 1 h; (c) 8-hydroxyquinoline, 
Et3N, CH2Cl2, rt, 24 h.4   
 
E. Chemical Properties 
Melting point: 117.4 °C;3 116–117 °C4  
Boiling point: Information could not be identified. 
Solubility: ~0.25 mg/mL in dimethylformamide/phosphate buffered saline (1:3; pH 
7.2); ~11 mg/mL in dimethylsulfoxide; ~16 mg/mL in dimethylformamide.2 
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F. Identification and Analysis  
Chemical and analytical data are available. 5F-PB-22 has also been employed for 
analytical purposes and featured in a range of routine methods of analysis 
associated with forensic and clinical investigations (Annex 2). The analytical 
determination of synthetic cannabinoid receptor agonists such as 5F-PB-22 in 
biological fluids can be a challenge, for example in cases where analytical 
methodologies are not specifically designed to detect these substances. In some 
instances (e.g. analysis of urine), the detection of metabolites may be the preferred 
approach. A number of 5F-PB-22 isomers are possible, for example by replacing 8-
hydroxyquinoline (section 2D above) with various regioisomers of 
hydroxyquinoline and hydroxyisoquinoline. Whether any of these compounds 
circulate on the drug market has not been reported but the ability to differentiate 
between them analytically might be important for clinical and forensic purposes.5   
 
3. Ease of Convertibility Into Controlled Substances 
No information has been found. However, 5F-PB-22 can be easily converted back to the 
carboxylic acid intermediate (Section 2D, compound (2)), which can then be transformed 
into many other synthetic cannabinoid receptor agonists (SCRAs). It seems conceivable 
that the carboxylic acid intermediate might also be convertible into a ketone function, 
found for example in AM-2201, i.e. [1-(5-fluoropentyl)-1H-indole-3-yl](naphthalen-1-
yl)methanone, which is listed in Schedule II of the Convention on Psychotropic Substances 
1971.    
 
4. General Pharmacology 
A. Routes of administration and dosage 
5F-PB-22, in its pure form but mostly as a synthetic constituent added to a plant 
matrix (e.g. damiana (Turnera diffusa) or marshmallow (Althaea officinalis), is 
normally smoked but reliable data about dosage are unavailable. The variations in 
drug composition and quantities frequently observed with many smoking mixtures 
(e.g.6, 7) make such estimation impossible for users despite of information may be 
displayed on a product label. Speculative doses (presumably based on 
smoking/inhalation) have been suggested: 1 mg (threshold); 1-3 mg (light); 3-5 mg 
(common); 5-8 mg (strong).8 
B.  Pharmacokinetics 
Information from clinical studies in humans is not available. A number of reports 
have been published that describe the biotransformation of 5F-PB-22 under in vitro 
conditions, either using human liver microsomes,9 pooled cryopreserved human 
hepatocytes,10 recombinant human carboxylesterases,11 or incubation studies using 
the fungus Cunninghamella elegans.12 The incubation with human hepatocytes 
resulted in the detection of 22 phase I and phase II metabolites with the ester 
hydrolysis product (1-(5-fluoropentyl)-1H-indole-3-carboxylic acid, 5F-PI-COOH) 
being the most dominant species, which has also been observed during an 
incubation study with human liver microseomes.9 Other transformations, either 
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alone or in combination, included hydroxylation and dihydroxylation, oxidative 
defluorination, carboxylation, epoxide hydrolysis and conjugation with glucuronic 
acid or cysteine. In addition to 5F-PI-COOH, two other major metabolites that 
originated via ester hydrolysis included 5F-PI-COOH-glucuronide indole 
hydroxylated 5F-PI-COOH. One major species still retaining the ester function 
originated from oxidative defluorination (to carboxylic acid at the terminal 5’-
carbon of the pentyl chain) whereas another was identified as the 5′-OH-PB-22-
glucuronide.10 It was also demonstrated that some of the 5F-PB-22 metabolites 
were identical to the products arising from metabolism of the defluorinated analog 
(PB-22).10 The ester hydrolysis product 5F-PI-COOH has also been detected in 
smoke condensates, which reflects pyrolysis-induced formation13 although it is 
unclear whether this carboxylic acid derivative would enter the brain for eliciting 
psychoactive effects. Interestingly, it has also been demonstrated that the detection 
of both 5F-PI-COOH and 5’-OH-PB-22 in human hair samples can result from 
external contamination rather than ingestion.13 An incubation of 5F-BB-22 (10 μM) 
with human recombinant carboxylesterases (CES1b/CES1A1 and CES2) in human 
serum (37 °C, 10 min) confirmed that these enzymes facilitated the ester 
hydrolysis.11 The correct identification of the parent molecule associated with drug 
intake can be challenging if one considers that structurally related metabolites might 
also show seemingly similar analytical features depending on the procedures used 
for their detection and identification. An example of this has recently been 
described where metabolites originally thought to originate from 5F-PB-22 were 
confirmed to arise from methyl 2-{[1-(5-fluoropentyl)-1H-indole-3-
carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PICA) instead.14 The 
identification of metabolites is also important to evaluate the question whether these 
could play a role in mediating the biological effects. It was recently reported that 
the 5F-PB-22 metabolite 5’-OH-PB-22 maintained the ability to activate both hCB1 
and hCB2 receptors. Under the investigated in vitro conditions (Table 1), the 5’-
COOH-PB-22 metabolite also displayed some activation (hCB1: 25.8%; hCB2: 
43.5%) whereas the hydrolyzed 5F-PI-COOH metabolite was inactive.15 
C. Pharmacodynamics 
A number of in vitro and in vivo studies have been carried out, which suggest that 
5F-PB-22, a SCRA, binds to and activates CB1 and CB2 receptors, and that it 
induces a number of biological responses that are also triggered by the naturally 
occurring phytocannabinoid Δ9-THC and other internationally controlled SCRAs 
(Tables 1 and 2).  
 
In vitro data: 
 
5F-PB-22 was more potent than Δ9-THC in the ability to activate G-protein-gated 
inwardly rectifying K+ channels (GIRKs) in mouse AtT20 neuroblastoma cells 
transfected with human CB1 and CB1 receptors. 5F-PB-22 was 101 times (hCB1) 
and 5.6 times (hCB2) more potent than WIN-55,212-2 and showed similar efficacy 
as a full agonist. In comparison to Δ9-THC, 5F-PB22 was 89 times more potent 
(hCB1). As a partial agonist, Δ9-THC only elicited 51% activation (hCB1) compared 
to a 13% efficacy (hCB2) that could only be achieved at a concentration of 10 μM. 
In this assay, the full agonist JWH-018 was 2.8 times more potent (hCB1) than 
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WIN-55,212-2 (similar efficacy) although the latter was 2 times more potent than 
the former (hCB2) with comparable efficacy (Table 1).
4 
 
When using the [35S]GTPγS turnover assay, it was reported that 5F-PB-22 acted as 
an agonist at the CB1 receptor (rat/mouse cortical homogenates). This compound 
was 5.5 times (rat CB1) and 9.5 times (mouse CB1) more potent than JWH-018. 
Relative to basal levels, 5F-PB-22 was also more effective than JWH-018 (Table 1). 
Activation was absent in CB1 knockout mice and also abolished following co-
incubation with CB1 receptor antagonist/inverse agonist AM-251.
18 
 
A G-protein coupled receptor activation assay, operating via drug-induced β-
arrestin 2/CB1/CB2 interaction, revealed that 5F-PB-22 was 45.5 times (hCB1) and 
18.3 time (hCB2) more potent than JWH-018. Furthermore, 5F-PB-22 was also 2.8 
times (hCB1) and 1.32 time (hCB2) more effective. In this study, it was also 
demonstrated that two main 5F-PB-22 metabolites, namely the ester hydrolysis 
product 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5F-PI-COOH) and 
quinolin-8-yl 1-(5-hydroxypentyl)-1H-indole-3-carboxylate (5’-OH-PB-22) 
retained activity (Table 1).15 Recently published data showed that 5F-PB-22 had 
sub-nanomolar affinity toward hCB1 and that its potency to activate the hCB1 
receptor was 416 times higher than that measured for the internationally controlled 
SCRA XLR-11.* 16  
 
Agonist-mediated inhibition of forskolin stimulated cAMP levels monitored in 
HEK-293 cells expressing the hCB1 receptor and compared relative to WIN-55,212-
2, 5F-PB-22 was determined to be a full agonist together with the SCRAs JWH-018 
and XLR-11 whereas CP-55,940 and HU-210 were identified as partial agonists. 
5F-PB-22 was 2 times more potent than WIN-55,212-2; 100 times more potent than 
XLR-11 and 6.3 times more potent than JWH-018. Under these assay conditions, 
JWH-073 was inactive (Table 1).17 From the perspective of evaluating living 
cellular functional responses to drug administration, hCB1-induced suppression of 
Ca2+ spiking was investigated in cultured rat hippocampal neurons (fluorescence 
detection and multi-electrode experiments). 5F-PB-22 induced significant overall 
suppression of Ca2+ spiking together with other SCRAs. HU-210 did not produce a 
suppression using the same concentration.17 In multi-electrode experiments, 5F-PB-
22 caused significant suppression at 10 μM and overall at 1 μM; effects were 
partially reversed by rimonabant.19  
 
                                               
* XLR-11: [1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone. 
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Table 1. 5F-PB-22 in-vitro data  Ref 
Functional activity: a 
5F-PB-22 at hCB1: EC50 = 2.8 nM (Emax = 108%); hCB2: EC50 = 11 nM (Emax = 101%) 
WIN-55,212-2 at hCB1: EC50 = 284 nM (Emax = 100%); hCB2: EC50 = 62 nM (Emax = 100%) 
Δ9-THC at hCB1: EC50 = 250 nM (Emax = 51%); hCB2: EC50 = 1157 nM (Emax = 13% at 10,000 nM) 
JWH-018 at hCB1: EC50 = 102 nM (Emax = 107%); hCB2: EC50 = 133 nM (Emax = 95%) 
 
Banister et al.4  
Receptor binding: b  
5F-PB-22 at hCB1: IC50/Ki = 0.27 nM  
XLR-11 at hCB1: IC50/Ki = 7.92 nM 
UR-144 at hCB1: IC50/Ki = 578.5 nM. 
 
Functional activity: b  
5F-PB-22 at hCB1: EC50 = 0.95 nM (Emax = 98.31%) 
XLR-11 at hCB1: EC50 = 359 nM (Emax = 104.95%) 
UR-144 at hCB1: EC50 = 1295 nM (Emax = 95.28%). 
 
Gatch et al.16 
Functional activity: c 
CB reporter assay 
5F-PB-22 at hCB1: EC50 = 0.84 nM (Emax = 278.8%); hCB2: EC50 = 0.70 nM (Emax = 131.9%) 
JWH-018 at hCB1: EC50 = 38.2 nM (Emax = 100%); hCB2: EC50 = 12.8 nM (Emax = 100%) 
JWH-122 at hCB1: EC50 = 71.7 nM (Emax = 173.4%); hCB2: EC50 = 9.2 nM (Emax = 94.0%) 
MAM-2201 at hCB1: EC50 = 60.5 nM (Emax = 174.7%); hCB2: EC50 = 2.7 nM (Emax = 97.4%) 
 
Activation of 5F-PB-22 metabolites: 
5F-PI-COOH at hCB1: Emax = 3.1%; hCB2: Emax = 4.6% (not significantly different from basal levels) 
5’-OH-PB-22 at hCB1: Emax = 171.0%; hCB2: Emax = 142.3% 
5’-COOH-PB-22 at hCB1: Emax = 25.8%; hCB2: Emax = 43.5% 
 
Cannaert et al.15 
Functional activity (hCB1): d  
 
Inhibition of forskolin stimulated cAMP levels:  
Efficacy relative to WIN-55,212-2: EC50 = 79 nM (Emax = 65%). 
 
5F-PB-22: EC50 = 39.8 nM (Emax = 67%), full agonist.  
CP-55,940: EC50 = 316 nM (Emax = 47%), partial agonist.  
HU-210: EC50 = 1585 nM (Emax = 35%), partial agonist.  
JWH-018: EC50 = 251 nM (Emax = 55%), full agonist.  
JWH-073: no activity. 
XLR-11: EC50 = 3981 nM (Emax = 65%), full agonist.  
AB-PINACA: EC50 = 79 nM (Emax = 69%), full agonist.  
 
hCB1-induced suppression of Ca2+ spiking in cultured rat hippocampal neurons: 
Compared to addition of blank. 
 
5F-PB-22: significant suppression of Ca2+ spiking at 10 μM. 
WIN-55,212-2: significant suppression at 10 μM. 
CP-55,940: significant suppression at 10 μM. 
HU-210: no suppression at 10 μM. 
XLR-11: significant suppression at 1 μM and10 μM (significant more suppression than AB-PINACA) 
AB-PINACA: significant suppression at 10 μM. 
 
Costain et al.17 
Receptor binding/rCB1 ([3H]CP-55,940):  e 
5F-PB-22: Ki = 0.13 nM  
5F-AKB-48: Ki = 0.87 nM 
JWH-018: Ki = 3.38 nM  
  
De Luca et al.18  
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[35S]GTPγS turnover: e 
 
5F-PB-22: rCB1: EC50 = 3.7 nM (Emax = 203%); mouse cortex CB1: EC50 = 4 nM (Emax = 183%) 
5F-AKB-48: rCB1: EC50 = 31 nM (Emax = 190%); mouse cortex CB1: EC50 = 28 nM (Emax = 167%) 
JWH-018: rCB1: EC50 = 20.2 nM (Emax = 163%); mouse cortex CB1: EC50 = 38 nM (Emax = 158%) 
Activation of G-proteins absent in CB1-KO mice; response also abolished when test drugs co-incubated with 
CB1 receptor antagonist/inverse agonist AM-251. 
 
Functional activity (hCB1): f  
 
hCB1-induced suppression of Ca2+ spiking in cultured rat hippocampal neurons (multi-electrode 
experiments): 
Percent change in number of spontaneous spikes before and after addition of 0.1% DMSO. 5F-PB-22 (10 
μM) caused significant decrease in spontaneous activity at all time points at 10 μM; overall decrease at 1 μM.  
Rimonabant (5 μM) significantly reversed 5F-PB-22-induced suppression (10 μM) at the first three time-
matched recordings and overall. WIN-55,212-2 (10 μM), WIN-55,212-3 (10 μM), HU-210 (10 μM), CP-
55,940 (10 μM) suppressed overall activity. JWH-018 (10 μM and 1 μM), XLR-11(10 μM), JWH-250 (10 
μM), and MAM-2201 (10 μM and 1 μM) suppressed overall activity. AB-PINACA caused significant 
suppression overall at both 10 μM and 1 μM but not at all investigated time points. “Overall“ suppression 
determined at the end of the recording time. For some compounds, suppression was not always considered 
significant at a number of earlier time points, thus, indicating suppression occurring at longer incubation 
times.   
 
Tauskela et al.19  
a Ref4: hCB1 and hCB2 receptors in stably transfected mouse AtT20 neuroblastoma cells; FLIPR membrane potential assay 
(blue) used for quantitative determination of K+ flux (hyperpolarization) linked to G-protein activation: G-protein-gated inwardly 
rectifying K+ channels (GIRKs); plates were incubated at ambient CO2 for 45 min at 37 °C; receptor activation and stimulation 
of cellular hyperpolarization led to decrease in fluorescence response. Comparison of test drugs was normalized against WIN-
55,212-2 response (set at 100% efficacy).  
b Ref16: Assays carried out by NovaScreen (PerkinElmer, Waltham, Massachusetts, USA) under contract with the National 
Institute on Drug Abuse Addiction Treatment Discovery Program; hCB1 receptors expressed in HEK-293 (binding) and CHO 
cells (functional activity). Further details not reported.  
c Ref15:  Application of NanoLuc binary technology (Promega): G-protein coupled receptor (GCPR) activation monitored via 
ligand-induced interaction of β-arrestin 2 with hCB1 and hCB2 receptors; transient transfection in HEK-293T cells; increase in 
bioluminescence measured via luciferase activity following CB–βarr2 interaction; cells transfected with either  
CB1−LgBiT/SmBiT−βarr2 combination or the CB2− SmBiT/LgBiT−βarr2 combination; efficacy reported relative to JWH-018 
set at 100%; test drug concentrations for efficacy tests was 1 μM. Several synthetic cannabinoid receptor agonist metabolites, e.g. 
originating from JWH-018, JWH-122, JWH-210, MAM-2201, EAM-2201, PB-22, 5F-PB22, retained the ability to activate the 
CB receptors.  
d Ref17: GloSensor™ cAMP assay; agonist-mediated inhibition of forskolin-stimulated cyclic adenosine monophosphate (cAMP) 
levels was monitored in live HEK293T cells transfected with human cannabinoid receptor 1 gene (CNR1) and pGloSensor-22F; 
efficacy determinations (% inhibition) relative to full agonist WIN-55,212-2. Synthetic cannabinoids were added 12 min prior to 
the addition of 10 μM forskolin. Luminescence was determined 15 min after forskolin addition; data were normalized to vehicle 
readings. Low-density primary hippocampal neuron cultures were loaded with a Ca2+ indicator and exposed to low Mg2+ buffer 
to induce spontaneous, transient increases in intracellular Ca2+ levels (Ca2+ spikes). Post-drug frequencies were normalized to 
pre-drug frequencies and post-drug % inhibition was calculated relative to the pre-drug condition.  
e Ref18: Receptor binding: male Sprague-Dawley rat cortical homogenates; membranes incubated with [3H]CP-55,940 (0.5 nM) 
for 1 h at 30 °C; [35S]GTPγS binding assay: rat and mouse cortical membranes used; mouse and rat brain membranes incubated 
with test drugs at 30 °C in assay buffer containing 0.1% BSA in the presence of 0.05 nM [35S]GTPγS and 30 μM GDP; final 
volume of 1 mL and incubation for 60 min; stimulation expressed relative to basal levels. For stimulation experiments test drugs 
(1 μM) added alone or in combination with CB1 receptor antagonist/inverse agonist AM-251 (0.1 μM). 
f Ref19: Hippocampal neurons plated at high density; each multi-electrode array served as its own internal control: two 20 min 
baseline recordings were performed prior to acquiring four 20 min recordings with a cannabinoid or DMSO vehicle present; 
online extracellular spike detection was used; activity was monitored over a total 80 min exposure of a cannabinoid, in 20 min 
recording sessions.  
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In vivo data: 
 
Currently available data suggest that 5F-PB-22 induces responses in animals that 
are also seen with Δ9-THC and other SCRAs, such as suppression of locomotor 
activity and decreased body temperature. 5F-PB-22 was 45 times more potent than 
Δ9-THC; 41 times more potent than XLR-11 and 31 times more potent than UR-
144† in resulting in decreased locomotor activity (Table 2).16 Furthermore, 5F-PB-
22 was found to fully substitute for Δ9-THC using the drug discrimination paradigm 
in mice where it was found to be 22 times more potent than the training drug. 
Microdialysis studies (nucleus accumbens shell) in male Sprague–Dawley rats 
revealed a modest increase in extracellular dopamine levels (~150%) (Table 2).18 
 
                                               
† UR-144: (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 
Table 2. In vivo assay data for 5F-PB-22 
Behavior / physiology / neurochemistry Ref 
Body temperature: a 
5F-PB-22: hypothermic effect (0.3-3 mg/kg) (> 1.5 °C) was observed. Maximum drop in body 
temperature observed with in the first hour of the 6 h monitoring period. Mean maximal 
hypothermia (at 3 mg/kg) was comparable to that induced by JWH-018.   
 
Rimonabant partially reversed hypothermic effects but CB2 receptor antagonist SR-144528 had 
only negligible effects on drug-induced hypothermia.  
 
Heart rate: a 
5F-PB-22: significant decrease in heart rate but more variable than body temperature data, 
possibly reflecting multiple determinants.  
 
Banister et al.4  
Locomotor activity: b 
5F-PB-22 (ED50 = 0.25 mg/kg), Δ9-THC (ED50 = 11.14 mg/kg), XLR-11 (ED50 = 10.29 mg/kg), 
and UR-144 (ED50 = 7.68 mg/kg) decreased locomotor activity as dose increased.  
 
Depressant effects of 5F-PB-22 (0.5 and 1.0 mg/kg) occurred within 10 min after injection and 
lasted 140 min. Maximal depressant effects were observed 0-30 min. 
 
Depressant effects of Δ9-THC occurred within 10-50 min after injection and lasted 90-140 min. 
Maximal depressant effects were observed 30-60 min after 10 and 30 mg/kg.  
 
Depressant effects of XLR-11 occurred within 10 min after administration and lasted 40-60 min. 
Maximal depressant effects of 10 and 30 mg/kg occurred 10-40 min after injection.  
 
Depressant effects of UR-144 occurred within 10 min after administration and lasted 60-90 min. 
Maximal depressant effects of 10 and 30 mg/kg occurred 10-40 min after injection.  
 
Drug discrimination: c 
5F-PB-22 (ED50 = 0.039 mg/kg), Δ9-THC (ED50 = 0.85 mg/kg), XLR-11 (ED50 = 0.18 mg/kg), and 
UR-144 (ED50 = 0.45 mg/kg), amongst other synthetic cannabinoids tested, fully substituted for 
the discriminative stimulus effect of Δ9- THC (3 mg/kg).   
 
5F-PB-22 (0.5 mg/kg) fully substituted from 30 to 60 min after administration, and drug-
appropriate responding was attenuated at the 120 min point; rates of responding decreased at 5, 15, 
30 and 60 min with marked suppression at 15 min after administration.  
 
XLR-11 (1 mg/kg) fully substituted from 5 to 15 min after administration, and drug-appropriate 
Gatch et al.16 
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5. Toxicology 
5F-PB-22, XLR-11 (1-500 μM, 24 h) and their pyrolysis products (10 mg of test drug 
burned and pyrolysis products isolated by solid phase extraction) were studied for exposure 
to SH-SY5Y, HepG2 and H9c2 cell lines and cell viability was assessed by the MTT and 
sulforhodamine B assay (SRB). 5F-PB- 22 was found to reduce viability of cardiac and 
neuronal cells whereas XLR-11 decreased viability of all three cell lines tested at lower 
concentrations. The pyrolysis products arising from 5F-PB-22 were stated to be more toxic 
than 5F-PB-22 and affected all assessed cell types. The XLR-11 pyrolysis products were 
stated to be less toxic than XLR-11 in the three cell lines.20 Any other information related 
to acute and chronic preclinical toxicology could not be identified. 
 
6. Adverse Reactions in Humans 
Reports associated with the presence of 5F-PB-22 in drug products and biofluids is 
summarized in Table 3. The total number of cases reported in the scientific literature that 
make a specific causal link with 5F-PB-22 is small.  
  
responding was nearly absent by 60 min. No effect of UR-144 on the response rate was observed. 
 
UR-144 (2.5 mg/kg) fully substituted at 15 and 60 min after administration, and drug-appropriate 
responding was diminished to <40% after 4 h. No effect of UR-144 on the response rate was 
observed. 
 
No other adverse effects were observed at the doses and time points tested. 
In vivo microdialysis: d 
5F-PB-22 administration (0.01 mg/kg, i.v.) led to a moderate but significant increase in 
extracellular dopamine levels in the nucleus accumbens shell dialysate at the 30 min (~ 145%) and 
40 min (~150%) point (relative to basal levels). In comparison, 5F-AKB-48 induced comparable 
increases at the 60, 10 and 150 min time point.  
De Luca et al.18  
a Ref4: male Wistar rats; biotelemetry transmitters placed in the peritoneal cavity; drugs administered (i.p.) in an 
ascending dose sequence (0.1, 0.3, 1, 3 mg/kg) (10 mg/kg if required) at the same time of day; data for heart rate and 
body temperature gathered at 1000 Hz (15 or 30 min bins). Data were recorded for 6 h post-injection.  
b Ref16: Locomotor activity: male ND4 Swiss-Webster mice (~8 weeks old); 16 infrared beams were located in the 
horizontal direction; dose range tested: Δ9-THC (1-30 mg/kg), 5F-PB-22 (0.1-1 mg/kg), UR-144 (1-30 mg/kg), XLR-
11 (1-30 mg/kg), and others, immediately before testing. Horizontal activity (interruption of photocell beams, 
ambulation counts) was measured for 8 h within 10-min periods; behavioural observations of each mouse were 
recorded at 30, 120, and 480 min after the highest dose tested.  
c Ref16: Drug discrimination: male Sprague-Dawley rats; trained to discriminate Δ9-THC (3 mg/kg) from vehicle  
using a two-lever choice methodology; each training session lasted 10 min; test drugs (amongst others): 
intraperitoneal injections of 5F-PB-22 (0.01-0.5 mg/kg, 30 min before start of session), UR-144 (0.1-5 mg/kg, 30 min 
before start) and XLR-11 (0.05-1 mg/kg, 15 min before start). Δ9-THC (3 mg/kg) controls were tested before the start 
of each compound evaluation. A repeated-measures design was used for time-course experiments.  
d Ref:18 Male Sprague-Dawley rats; vertical dialysis probes implanted in nucleus accumbens (NAc) shell and core and 
medial pre-frontal cortex (mPFC); test drugs administered intravenously; 5F-PB-22: 0.01 mg/kg; 5F-AKB-48: 0.1 
mg/kg; STS-135: 0.15 mg/kg; CB1 receptor antagonist/inverse agonist AM-251 administered intraperitoneally (1 
mg/kg); dopamine levels determined by HPLC-ECD; only the NAc shell dialysate was analyzed after 5F-PB-22 
treatment.  
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Table 3. Case reports associated with the involvement of 5F-PB-22 reported in the scientific literature. 
Year Cases Patient, 
age 
Comments (examples) Ref 
2014 1 M, 17 One of four death cases analyzed between July and October 2013;a began ‘gasping for 
air and fell to the ground’ in the morning following consumption of alcohol and other 
drugs including synthetic cannabinoids and pronounced dead at medical center; 
autopsy did not reveal significant injuries or natural diseases. Toxicology findings: 
femoral blood concentration for 5F-PB-22 of 1.1 ng/mL, an ethanol concentration of 
0.033 g/dL, amiodarone (administered during resuscitative efforts) and caffeine. 
Behonick et al.21 
2014 1 M, 27 One of four death cases analyzed between July and October 2013; arrived at 
emergency room ‘appearing quite ill and diaphoretic’. Patient confirmed history of 
marijuana use of several times per week. Evaluation indicated severe liver injury, 
severe coagulopathy, acute kidney injury, acute respiratory failure, hypoxemia, severe 
anion gap, metabolic and lactic acidosis; clinical condition deteriorated over the next 
12 h; progressed to critically ill status due to circulatory failure, respiratory failure, 
central nervous system failure, renal failure and severe metabolic derangement. 
Autopsy revealed cause of death to be fulminant liver failure in the setting of THC 
(marijuana) and 5F-PB-22 (synthetic cannabinoid) exposure. The manner of death was 
certified as undetermined. Toxicology findings: a pair of hospital serum specimens 
obtained a day before death (~9.5 h apart) indicated presence of THCCOOH (246 and 
176 ng/mL); piperacillin, levofloxacin (presumably reflecting treatment) also detected. 
A different serum specimen, collected ~7 h before death revealed 5F-PB-22 at 1.3 
ng/mL and lorazepam (19.5 ng/mL) (presumably reflecting treatment). 
Behonick et al.21 
2014 1 M, 18 One of four death cases analyzed between July and October 2013; pronounced dead at 
home following a night of partying; reported to have consumed numerous beers, 
mixed alcoholic beverages and smoked synthetic marijuana (K2/Spice); later 
discovered unresponsive, not breathing, cool to the touch and pulseless; autopsy: 
bilateral pulmonary vasocongestion and congestion in the abdominal organs (liver, 
spleen and kidneys); concentration of 1.5 ng/mL 5F-PB-22 determined in iliac blood; 
cause of death was attributed to sudden death, in association with synthetic 
cannabinoid use; manner of death classified as accident.  
Behonick et al.21 
2014 1 M, 19 One of four death cases analyzed between July and October 2013; was found dead after 
returning from a party. Autopsy: included bilateral pulmonary edema, necrotizing 
granulomatous inflammation with histoplasma microorganisms and congestion of 
viscera. Toxicology findings: 5F-PB-22 at 1.5 ng/mL in superior vena cava blood; 
stated cause of death was suspected acute drug intoxication using the synthetic 
cannabinoid 5F-PB-22. The manner of death was accident. 
Behonick et al.21 
2014 6 NR b Report sent to DEA from the Mansfield Division of Police Forensic Science 
Laboratory in Mansfield, Ohio (USA); was stated to have included 
incident/investigative public narratives and descriptions of physical symptoms and 
observations of users such as unconsciousness, agitation, violent behavior; details not 
reported. Timeframe: January to May 2013. 
DEA22 
2014 2 M, 17 
M, 18 
Seventeen-year-old male’s cause of death listed “5F- PB-22 intoxication.” Autopsy 
findings of 18 year old male reported as a fatal cardiac arrhythmia and/or fatal seizure 
in association with 5F-PB-22 use. Three separate postmortem cases stated to be under 
investigation. Whether any of these cases are similar to the ones published by 
Behonick et al.21 is not clear. 
DEA22 
2015 1 M, 23 Recreationally smoked a synthetic cannabinoid cigarette (trade name K2) at home and 
6 h later suffered what his wife described as generalized tonic–clonic seizure activity, 
including urinary incontinence and tongue lacerations; presented later at emergency 
department with nausea, dry mouth, and vomiting. Neurologic and cardiopulmonary 
examination was normal; patient experienced second episode of seizure activity three h 
after discharge. Use history: smoking synthetic cannabinoids more or less daily for the 
previous several years with no history of seizures. Blood biochemistry was normal 
except for potassium of 3.3 mM.  
Two plasma samples were taken (5.5 and 8.3 h after the last exposure) and analyzed. 
5.5 h / 8.3 h samples (pg/mL): BB-22 (97/94), AM-2233 (148/125); PB-22 (75.84); 5F-
Schep et al.23 
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PB-22 (85/91), JWH-122 (N-cyclohexylmethyl) (9/13).   
“Clusters of cases of adverse health effects or severe toxic effects and deaths associated with synthetic cannabinoid 
product use.” Analysis of clinical samples; details not reported. Locations: USA.  
July 2013: One fatal and one non-fatal intoxication detected in Davenport, IA. 
October 2013: One fatal and one non-fatal intoxication detected in Waverly, NE 
Trecki et al.24  
2016 1 F, 19 Reported to have purchased three products from a headshop: two new psychoactive 
substances (sachets of “cannabis tea” and “mushroom tea”) as well as two LSD 
blotters. After the “cannabis tea” was smoked and the two LSD blotters and 
“mushroom tea” were ingested, the patient became tachycardic (HR 128), developed 
seizures, agitation, visual hallucinations as well as suspected serotonergic toxicity 
(sustained ankle clonus 20-30 beats) 1-2 hours after use. Patient was treated with 1 mg 
of intravenous midazolam and symptoms/signs resolved within 13 h. Patient had 
medical history of depression, treated with fluoxetine and citalopram. Samples 
collected from patient at 5 h (plasma) and 17 h (blood and urine) post exposure.  
 
Toxicology findings: initial plasma sample (5 h) contained 5F-PB-22 (200 pg/mL) and 
two 5F-AKB-48 metabolites (5F-AKB-48 adamantyl hydroxy (900 pg/mL) and 5F-
AKB-48 desfluoro hydroxypentyl (5000 pg/mL)), citalopram (10-20 ng/mL), diazepam 
10-20 ng/mL and fluoxetine metabolites. Seventeen hours: 5F-PB-22 (40 pg/mL), two 
5F-AKB-48 metabolites (150 pg/mL and 800 pg/mL), citalopram (10-20 ng/mL), 
fluoxetine (20-30 ng/mL) and diazepam (40-50 ng/mL). Urine sample (17 h) contained 
metabolites of 5F-AKB-48 (1-5 ng/mL range), citalopram (approx. 250 ng/mL), 
fluoxetine 40 ng/mL and diazepam metabolites (oxazepam 200 ng/mL, temazepam 100 
ng/mL) and zolpidem metabolites (10-50 ng/mL). The detection of diazepam and 
zolpidem might have indicated potential adulteration of drugs (not given during 
treatment and not reported by user). 
Abouchedid et 
al.25 
2017 1 M, 36 Presenting at emergency department between January-July 2015. Self reported use: ” 
“Black Mamba”and crack. Observations at admission: heart rate: 55 bpm; temp: 35.6 
°C; Glasgow coma scale: 14; length of stay: 3.0 h. Serum analysis (ng/mL): 5F-AKB-
48: 4 and 32 for metabolites; 5F PB-22: 0.2. 
Abouchedid et 
al.26 
2017 1 M, 22 Presenting at emergency department between January-July 2015. Self reported use: 
”Herbal A” and alcohol. Observations at admission: heart rate: 52 bpm; temp: 35.8 °C; 
Glasgow coma scale: 14; length of stay: 1.7 h. Serum analysis (ng/mL): 5F-AKB-48: 2 
and 6.8 for metabolites; BB-22: 0.06; 5F-PB-22: 0.4.  
Abouchedid et 
al.26 
2017 1 M, 18 Presenting at emergency department between January-July 2015. Self reported use: 
Unknown. Observations at admission: heart rate: 74 bpm; temp: 36.4 °C; Glasgow 
coma scale: 15; length of stay: 2.5 h. Serum analysis (ng/mL): 5F-AKB-48: 0.4 and 2.4 
for metabolites; 5F-PB-22: 0.36. 
Abouchedid et 
al.26 
2017 1 M, 38 Presenting at emergency department between January-July 2015. Self reported use: 
Unknown. Observations at admission: heart rate: 96 bpm; temp: 35.4 °C; Glasgow 
coma scale: 15; length of stay: 7.8 h. Serum analysis (ng/mL): 5F-AKB-48: 0.08 and 
0.4 for metabolites; 5F-PB-22: 0.03. Other drug detected: carbamazepine. 
Abouchedid et 
al.26 
2017 1 F, 24 Presenting at emergency department between January-July 2015. Self reported use:  
“Pirate vertex” and alcohol. Observations at admission: heart rate: 128 bpm and 
agitation; length of stay: 3.1 h. Serum analysis (ng/mL): 5F-AKB-48: 7.6 and 3 for 
metabolites; 5F-PB-22: 0.08; AB-CHMINACA: 0.280. Other drugs detected: 
quetiapine, citalopram/escitalopram and metabolites, lorazepam.  
Abouchedid et 
al.26 
2017 1 M, 44 Presenting at emergency department between January-July 2015. Self reported use: 
cocaine and cannabis. Observations at admission: heart rate: 72 bpm; temp: 37 °C; 
Glasgow coma scale: 15; seizure, psychosis; length of stay: 4.9 h. Serum analysis 
(ng/mL): main drug detected: cocaine and metabolite; levamisole/tetramisole; 5F-
AKB-48: 0.45 and 1.2 for metabolites; 5F-PB-22: 0.08.  
Abouchedid et 
al.26 
2017 1 F, 24 Presenting at emergency department between January-July 2015. Self reported use: 
white powder. Observations at admission: heart rate: 79 bpm; temp: 35.5 °C; Glasgow 
coma scale: 15; chest pain; length of stay: 2.3 h. Serum analysis (ng/mL): main drugs 
detected: ethylphenidate and methiopropamine; also levamisole/tetramisole; 5F-AKB-
48: 0.4 and 0.6 for metabolites; 5F-PB-22: 0.08. 
Abouchedid et 
al.26 
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2017 15 NR Review of cases associated with motor vehicle collisions and ingestion of synthetic 
cannabinoid receptor agonists in Japan. Time frame: 2012-2014, with 5F-PB-22 being 
dominant between spring and winter 2013; not detected before of after that time period. 
Detection of 5F-PB-22 in 6 case samples: range 0.274-0.93 ng/mL (n = 5), median 0.35 
ng/mL. In three cases, further information was available: a) driver looked emotionless 
and kept flooring accelerator pedal even after the crash; driver had no memory of the 
crash; b) driver lost consciousness; recovered after 3.5 h but had no memory of the 
crash; c) driver did not step off the accelerator pedal after crash and kept on moving the 
steering wheel and gear lever in a stereotyped manner; driver had no memory of 
abnormal driving. NNE-1 was also detected together with 5F-PB-22.  
Kaneko27 
a It appears that some of the case data were also published by Bottei in an abstract form.28 
b NR: not reported. 
 
7. Dependence Potential 
A. Animal Studies 
No information available. 
B. Human Studies 
Three male (aged 17-38 years) and three female (aged 20-42 years) dependent users 
(included based on the Severity of Dependence Screener) of herbal mixtures 
containing 5F-AKB-48‡ and 5F-PB-22 were interviewed following a structured 
interview guide. Users reported agitation, suicidal ideation and self-harm 
ideologies, and incidences of sibling and peer suicide during times of withdrawal 
and when attempted to restricted use or self-detoxify. The urge to re-dose has been 
reported by the users.29 However, it was not reported whether 5F-PB-22 was 
present in the herbal mixtures and biofluids.   
 
8. Abuse Potential 
A. Animal Studies 
As summarized in Tables 1 and 2 (Section 4C), 5F-PB-22 was shown to share some 
cannabinoid-like properties, such as binding to and activation of CB1 and CB2 
receptors and depression of locomotor activity. A moderate increase in extracellular 
dopamine levels have been identified in an in vivo microdialysis study (nucleus 
accumbens shell) using conscious rats. One drug discrimination study revealed that 
5F-PB-22 (more potently) substituted fully for Δ9-THC although a decrease in 
response rates was also observed (Table 2). These data indicate that 5F-PB-22 may 
have abuse liability and further studies are warranted to investigate this further. 
B. Human Studies 
See 7B. 
 
                                               
‡ 5F-AKB-48: N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 
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9. Therapeutic Applications and Extent of Therapeutic Use and 
Epidemiology of Medical Use 
5F-PB-22 is not known to have any therapeutic applications. 
 
10. Listing on the WHO Model List of Essential Medicines 
5F-PB-22 is not listed on the WHO Model List of Essential Medicines (20th List) or the 
WHO Model List of Essential Medicines for Children (6th List). 
 
11. Marketing Authorizations (as a Medicinal Product) 
5F-PB-22 is not marketed as a medicine. 
 
12. Industrial Use 
5F-PB-22 has no reported industrial use. 
 
13. Non-Medical Use, Abuse and Dependence 
Household or subpopulation surveys that specifically probe for prevalence of 5F-PB-22 
could not be identified in the currently available literature. Epidemiological data, such as 
prevalence of use, abuse and dependence information, are not available specifically for 5F-
PB-22. However, heavy use of synthetic cannabinoid receptor agonists has been associated 
with problematic withdrawal symptoms (e.g.29-31) and further research is needed to 
investigate the underlying mechanisms.  
 
Also see Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
 
14. Nature and Magnitude of Public Health Problems Related to Misuse, 
Abuse and Dependence 
The majority of available synthetic cannabinoid products (including those containing 5F-
PB-22) is sold in the form of herbal mixtures, and designed for smoking purposes. It is 
common for retailers to purchase bulk quantities of the synthetic substance and to add the 
synthetic material to a variety of vegetable matter as the plant base. Products sold as herbal 
smoking mixtures frequently change in drug composition and quantity, often without 
indications on product labels, which results in challenges to unambiguously correlate 
harms to public health with a specific drug such as 5F-PB-22. 
 
The consumption of these products might be attractive to a variety of users, such as regular 
users of cannabis and those who might wish to avoid drug-testing procedures resulting in 
positive cannabis findings. Ease of access, and perceived lack of control might equally be 
of interest to some users. The high potency associated with many synthetic cannabinoids 
carries the risk of accidental overdose and potentially severe adverse events but 
information specific to 5F-PB-22 is limited. As highlighted in Section 6 (Table 3), the 
ingestion of 5F-PB-22 products has been implicated in cases of impaired driving and motor 
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vehicle collisions,27 which adds a public health dimension. Although not specific to 5F-PB-
22, there are indications that socially vulnerable and stigmatized drug users, for example 
found in homeless and prison populations, are increasingly associated with problematic use 
of synthetic cannabinoid receptor agonist products.32-35   
 
Also see Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
  
15. Licit Production, Consumption and International Trade 
5F-PB-22 is available as standard reference material and produced for scientific research 
by a number of commercial suppliers. Other uses could not be identified. 
 
16. Illicit Manufacture and Traffic and Related Information 
Reports have been received from the European Early-Warning System on new 
psychoactive substances that 5F-PB-22 (first detected in 2013) was encountered in seizures 
and collected specimen (herbal mixtures or powders) in Belgium, Sweden, Latvia, 
Germany, Denmark, United Kingdom, Romania, Turkey, Lithuania, Croatia, Luxembourg, 
France, Hungary, Norway, Italy, Czech Republic, Bulgaria and Spain.36 
 
5F-PB-22 detections started to appear and peaked in United States of America (USA) in 
2013. The National Forensic Laboratory Information System (NFLIS), which is dedicated 
to the collection of drug cases submitted by State and local laboratories in the USA, 
registered a drop in reports from 2015 onward (Table 4), presumably as a consequence of 
issuing an order to temporarily schedule 5F-PB-22 into Schedule I of the Controlled 
Substances Act.37-39 5F-PB-22 has also been seized in kilogram quantities.22 
 
Table 4. Number of reports received by the U.S. National Forensic Laboratory 
Information System (NFLIS) related to detections of 5F-PB-22 in law enforcement 
operations. 
Year a Numbers XLR-11 MDMA Meth b Ref 
2013 (MY) 544 11,273 2,423 100,045 NFLIS40 
2013 (AR) 1,952 19,243 4,798 206,784 NFLIS41 
2014 (MY) c 708 6,316 2,224 117,318 NFLIS42 
2014 (AR) 1,067 11,001 4,902 236,175 NFLIS43 
2015 (MY) 184 3,769 2,421 133,374 NFLIS44 
2015 (AR) 408 6,973 5,188 277,823 NFLIS45 
2016 (MY) NR d 1,409 2,901 155,535 NFLIS46 
a MY: mid-year report (January to June); AR: annual report (January to December). 
b Meth: methamphetamine. 
c Revised March 2016. 
d Not reported but 5F-PB-22 related numbers might have been covered under the item 
“other synthetic cannabinoids”. 
 
Detections of 5F-PB-22 have also been reported to UNODC’s Early Warning Advisory on 
New Psychoactive Substances.47 5F-PB-22 was reported by 28 countries in 2013, 27 
countries in 2014, 29 countries in 2015, and 7 countries in 2016 (as of 08 August 2017).  
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17. Current International Controls and Their Impact 
5F-PB-22 is not controlled under the 1961, 1971 or 1988 United Nation Conventions. 
 
18. Current and Past National Controls 
Refer to Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
 
19. Other Medical and Scientific Matters Relevant for a Recommendation on 
the Scheduling of the Substance 
Not applicable. 
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Annex 1: Report on WHO Questionnaire for Review of Psychoactive 
Substances for the 39th ECDD: Evaluation of 5F-PB-22 
 
Please refer to separate Annex 1 document published on ECDD website 
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Annex 2: Studies associated with the detection and chemical analysis 
of 5F-PB-22 (amongst other substances) published in the scientific 
literature. 
 
Techniques a Comment Reference 
GC-HR-MS, LC-QTOF-
MS/MS, NMR, FT-IR 
Characterization of seized/collected compounds. Shevyrin et al.1, 2 
Melting point, 1H-NMR, GC-
MS, ATR-FT-IR 
Characterization of reference material. SWGDRUG3 
LC-QqQ-MS/MS Postmortem blood and antemortem serum analyses.  Behonick et al.4  
Not reported Postmortem analysis (presumably identical cases described by Behonick et 
al.4) 
Bottei5 
1H-NMR Analysis of reference material. Huang et al.6 
LC-QqQ-MS/MS In vitro metabolism studies using human liver microsomes. Takayama et al.7 
Not reported. Analysis of products purchased between November 2013 and May 2014 in 
Japan. 
Uchiyama et al.8 
LC-QqQ-TOF-MS In vitro metabolism studies using pooled human hepatocytes. Wohlfarth et al.9 
Melting point, NMR, ESI-MS, 
elemental analysis 
Synthesis and use in pharmacological investigations. Banister et al.10 
LC-TOF-MS, GC-MS Analysis of reference material. Marginean et al.11 
LC-Q-Orbitrap-MS Plasma analysis following intoxication case. Schep et al.12 
LC-Q-Orbitrap-MS/MS In vitro metabolism studies using human liver microsomes and 
recombinant carboxylesterases. 
Thomsen et al.13 
Not reported Summary of cases related to acute intoxications. Trecki et al.14 
LC-Q-Orbitrap-MS/MS Plasma, blood and urine analysis following intoxication case. Abouchedid et al.15 
LC-QqQ-MS/MS Analysis of urine samples. Cannaert et al.16 
Voltammetry  Detection of reference material spiked in artificial saliva. Dronova et al.17 
LC-QqQ-MS/MS Analysis of hair samples. Franz et al.18 
LC-MS/MS Analysis of serum and urine samples obtained from acute intoxication 
cases. 
Müller et al.19 
DART-MS, LC-QTOF-MS Analysis of reference material and method application to samples. Nie et al.20 
LC-Q-Orbitrap Analysis of serum samples following acute intoxications. Abouchedid et al.21 
GC-MS, 1H-NMR Analysis of herbal mixtures. Frinculescu et al.22 
Not reported Review of cases involving motor vehicle collisions in 2013 and blood 
analysis. 
Kaneko23 
GC-MS(/MS), LC-PDA, LC-
MS 
Characterization of 5F-PB-22 and regioisomers and analysis of herbal 
mixtures. 
Kohyama et al.24 
GC-cold-EI-MS Analysis of reference material. Smolianitski-Fabian 
et al.25 
LC-QTOF-MS/MS Metabolism studies using the fungus Cunninghamella elegans. Watanabe et al.26 
 
a GC: gas chromatography; MS: mass spectrometry; MS/MS: tandem mass spectrometry; HR: high resolution; LC: liquid 
chromatography (various forms); Q: quadrupole; TOF: time-of-flight; NMR: nuclear magnetic resonance spectroscopy; FT-IR: Fourier 
transform infrared spectroscopy; ATR: attenuated total reflectance; QqQ: triple quadrupole; ESI: electrospray ionization; DART: direct 
analysis in real time; PDA: photo diode array detector. 
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